Jeff Patrick Gehl bought $56k of SLE
director at Super League Enterprise, Inc.. 50,000 shares at an average of $1.11, traded Jul 18, 2024, filed Jul 19, 2024.
Score components
- +15RoleDirector
- +7Trade size$56k at market
- +10Relative to holdingsHoldings up 88%
- +8Price context86% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m 0.0%, 3m -16.2%, 6m -45.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-019831, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 18, 2024 | POpen-market purchase Common Stock | +50,000 | $1.11 | $56k | 106,547 | Jul 19, 2024 |
Related signals
Other insiders at Super League Enterprise, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | SLEsell Super League Enterprise, Inc. | Mark Jung director | $117 137 shares | -1% | |
| 42Moderate | SLEbuy Super League Enterprise, Inc. | Jeff Patrick Gehl director | $68k 50,000 shares | +47% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.